ImmuCell Historical Cash Flow
| ICCC Stock | USD 3.70 0.04 1.07% |
Analysis of ImmuCell cash flow over time is an excellent tool to project ImmuCell future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Non Cash Items of 273.9 K or Capital Expenditures of 1.6 M as it is a great indicator of ImmuCell ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining ImmuCell latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ImmuCell is a good buy for the upcoming year.
ImmuCell |
About ImmuCell Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in ImmuCell balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which ImmuCell's non-liquid assets can be easily converted into cash.
ImmuCell Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from ImmuCell's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into ImmuCell current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuCell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.At present, ImmuCell's Depreciation is projected to increase significantly based on the last few years of reporting. The current year's Other Non Cash Items is expected to grow to about 273.9 K, whereas Change To Inventory is projected to grow to (1.7 M).
ImmuCell cash flow statement Correlations
Click cells to compare fundamentals
ImmuCell Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ImmuCell cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (186.6K) | 425.7K | (997.5K) | (2.9M) | (1.8M) | (1.7M) | |
| Free Cash Flow | (1.2M) | (2.8M) | (1.7M) | (5.5M) | (6.6M) | (6.2M) | |
| Change In Working Capital | (1.1M) | 532.3K | (1.6M) | (1.8M) | (2.3M) | (2.2M) | |
| Begin Period Cash Flow | 2.5M | 6.3M | 6.9M | 10.2M | 5.8M | 6.1M | |
| Other Cashflows From Financing Activities | 7.8M | (53.1K) | 14.0K | 11.4K | (81.5K) | (77.5K) | |
| Depreciation | 2.3M | 2.3M | 2.5M | 2.5M | 2.7M | 2.9M | |
| Other Non Cash Items | 19.4K | (780.4K) | 18.6K | 28.8K | 260.8K | 273.9K | |
| Capital Expenditures | 1.4M | 4.1M | 2.6M | 4.0M | 1.9M | 1.6M | |
| Total Cash From Operating Activities | 233.5K | 1.3M | 954.2K | (1.5M) | (4.7M) | (4.4M) | |
| Net Income | (1.3M) | (1.0M) | (78.3K) | (2.5M) | (5.8M) | (5.5M) | |
| End Period Cash Flow | 6.3M | 6.9M | 10.2M | 5.8M | 978.7K | 929.8K | |
| Change In Cash | 3.8M | 656.6K | 3.2M | (4.4M) | (4.8M) | (4.6M) | |
| Total Cash From Financing Activities | 6.9M | 1.9M | 3.9M | 1.1M | 1.8M | 1.4M | |
| Sale Purchase Of Stock | 3.8M | 96.3K | 8.3M | 9.0 | 10.35 | 9.83 | |
| Change To Account Receivables | (704.9K) | (159.6K) | (897.4K) | 935.6K | (426.8K) | (448.1K) | |
| Change To Liabilities | (88.7K) | 299.9K | 245.8K | 341.6M | 392.9M | 412.5M | |
| Stock Based Compensation | 313.1K | 253.1K | 144.3K | 266.2K | 368.9K | 387.3K | |
| Total Cashflows From Investing Activities | (3.4M) | (2.6M) | (1.6M) | (4.0B) | (3.6B) | (3.4B) | |
| Investments | (2.0M) | (2.6M) | (1.6M) | (4.0M) | (3.4M) | (3.2M) | |
| Change Receivables | (306.3K) | 411.7K | (732.6K) | (132.4K) | (119.1K) | (125.1K) | |
| Net Borrowings | (1.4M) | 2.0M | (368.3K) | 1.1B | 1.3B | 1.3B | |
| Cash And Cash Equivalents Changes | (1.4M) | (1.3M) | 3.8M | 656.6K | 755.1K | 610.6K | |
| Cash Flows Other Operating | 301.8K | 116.8K | (87.7K) | (983.4K) | (885.0K) | (840.8K) | |
| Other Cashflows From Investing Activities | 36.3K | (14.1K) | (8.9K) | 45.6K | 52.4K | 55.1K | |
| Change To Netincome | 357.3K | (644.6K) | 186.0K | 287.4M | 330.5M | 347.0M | |
| Change To Operating Activities | (115.4K) | (33.7K) | 26.6K | (161.4M) | (145.2M) | (138.0M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ImmuCell offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ImmuCell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immucell Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immucell Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuCell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.63) | Earnings Share (0.49) | Revenue Per Share 2.991 | Quarterly Revenue Growth 0.549 | Return On Assets (0.05) |
The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.